Biofrontera AG

  • WKN: 604611
  • ISIN: DE0006046113
  • Land: Deutschland

Nachricht vom 22.11.2019 | 17:00

Biofrontera AG: Biofrontera to Participate in Upcoming Investor Conferences

DGAP-News: Biofrontera AG / Key word(s): Conference
22.11.2019 / 17:00
The issuer is solely responsible for the content of this announcement.

Biofrontera to Participate in Upcoming Investor Conferences

Leverkusen, Germany, November 22, 2019 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced its participation at the following events:

Event: Deutsches Eigenkapitalforum / Analyst conference
Format: Presentation & 1x1 Meetings
Date: Monday, November 25, 2019
Time: 5:00pm CET
Location: Sheraton Frankfurt Airport Hotel & Conference Center, Frankfurt/Main, Germany


Event: Benchmark Discovery 1x1 Conference
Format: 1x1 Meetings
Date: Wednesday, December 4, 2019
Location: The New York Athletic Club, New York, NY

Event: 12th Annual LD Micro Main Event
Format: Presentation & 1x1 Meetings
Date: Wednesday, December 11, 2019
Time: 10:00am PT
Location: Luxe Sunset Boulevard Hotel, Los Angeles, CA: Track 2
-End-

 

Enquiries, please contact:
Biofrontera AG

Thomas Schaffer, Chief Financial Officer

+49 (0) 214 87 63 2 0
ir@biofrontera.com
IR UK: Seton Services
Toni Vallen

+44(0) 207 229 0805
IR and PR US: The Ruth Group
IR: Tram Bui
PR: Kirsten Thomas

+1 646-536-7035
+1 508-280-6592

 

About Biofrontera:

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics.

The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company's lead product is the combination of Ameluz(R), a topical prescription drug, and medical device BF-RhodoLED(R) for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz(R) has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets the prescription medication XepiTM for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos(R), which offers specialized care for damaged or diseased skin.

Biofrontera is the first German founder-led pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 by the current CEO Prof. Dr. Hermann Lübbert and is listed on the Frankfurt Stock Exchange (Prime Standard) and on the US NASDAQ.www.biofrontera.com.



22.11.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Solutiance: Hohe Wachstumsdynamik durch den Ausbau des Plattformgeschäfts erwartet

Im ersten Halbjahr 2020 konnte Solutiance den eingeschlagenen Wachstumskurs fortsetzen und im Rahmen dessen die Gesamtleistung (Umsatz zzgl. Bestandsveränderungen) um rund 75 % auf 0,66 Mio. € (1. HJ 2019: 0,38 Mio. €) erhöhen. Das Unternehmen erwartet für das Gesamtjahr durch den weiteren Ausbau der softwarebasierten Dienstleistungen einen Umsatzsprung im Vergleich zum Vorjahr auf rund 3 Mio. €. Bei einem von uns ermittelten Kursziel von 4,85 € vergeben wir das Rating KAUFEN.

Aktuelle Research-Studie

Aroundtown SA

Original-Research: Aroundtown SA (von First Berlin Equity Research GmbH): BUY

22. September 2020